Who
Jeffrey M. Jonas
Director
Company insider
Files Form 4 as: Director, COMPASS Pathways; Director, Generation Bio Co; Chief Innovation Officer, Sage Therapeutics; Director, Karuna Therapeutics; Executive Vice President, Ionis Pharmaceuticals.
In numbers
- Trades disclosed
- 162
- Buys
- 3
- Sells
- 13
- Bought
- $601K
- Sold
- $90.9M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 1 Feb 2007
- Last trade
- 27 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 May 2026filed 29 May 2026 | CMPS COMPASS Pathwaysoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,110 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | CMPS COMPASS Pathwaysoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,110 at $0.00 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —4,246 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —5,200 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —4,246 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —5,200 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —1,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —1,920 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —2,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —6,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,920 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —2,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —6,000 | filing |
| 29 Oct 2025filed 31 Oct 2025 | CMPS COMPASS Pathwaysoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,000 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | Generation Bio Cooption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 10 Jun 2024filed 11 Jun 2024 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | Generation Bio Cooption or derivative | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.